GeoVax Labs, Inc. announced today preliminary top-line results from GV-TH-01, a Phase 1 clinical trial investigating the ability of the Company's GOVX-B11 vaccine to control HIV infections in patients who initiated antiretroviral drug treatment within 18 months of seroconversion.
http://www.biospace.com/news_story.aspx?StoryID=320745&full=1
http://www.biospace.com/news_story.aspx?StoryID=320745&full=1
No comments:
Post a Comment